News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
New Studies Expand the Large Body of Data on the Important Role of an Arthritis Protein; 14-3-3eta Blood Test
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world's...
NRC and Augurex collaborate to improve treatments for rheumatoid arthritis
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Arthritis Blood Test: 14-3-3eta Ground-Breaking Data
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
Vancouver, BC – October 25, 2013 - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking...
Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3η...
Exciting Update From the World of BC Biotechnology
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation's clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia (Dr....
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
New Studies Expand the Large Body of Data on the Important Role of an Arthritis Protein; 14-3-3eta Blood Test
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world's...
NRC and Augurex collaborate to improve treatments for rheumatoid arthritis
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Arthritis Blood Test: 14-3-3eta Ground-Breaking Data
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
Vancouver, BC – October 25, 2013 - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking...
Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3η...
Exciting Update From the World of BC Biotechnology
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation's clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia (Dr....
Protein Measured by a Blood Test Marks Joint Erosions in Arthritis
At Europe's premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact